Keenova Shares Promising Clinical Findings on TERLIVAZ® at 2026 Digestive Disease Week

Keenova Therapeutics, based in Dublin, made headlines today by announcing a significant clinical presentation on TERLIVAZ® (terlipressin) at the highly anticipated Digestive Disease Week (DDW) set to take place from May 2-5, 2026. This new analysis focuses on hepatorenal syndrome-acute kidney injury (HRS-AKI), a critical health issue affecting patients with advanced liver disease.

The presentation aims to reveal pivotal findings that advance our comprehension of this severe condition, characterized by a fast decline in kidney function that poses stark risks to patient survival. Dr. Marek Honczarenko, Executive Vice President and Chief Scientific Officer at Keenova, expressed enthusiasm about sharing these important insights, stating, "We are pleased to share these findings with the medical community, as they expand the clinical evidence and advance our understanding of this challenging and rapidly progressive condition." The research highlights how the usage of TERLIVAZ® has informed clinical decisions and implications for patient care in hospitals across the United States.

Understanding HRS-AKI

Hepatorenal syndrome is a severe condition that generally affects adults with significant liver damage, leading to acute kidney injury. It is crucial to address because it is associated with high morbidity and mortality rates. A detailed analysis of national data from the U.S. indicates a troubling increase in the number of patients diagnosed with HRS over recent years, escalating from approximately 42,930 cases in 2018 to over 63,000 in 2023. This reinforces the urgent need for effective treatments and ongoing research in this domain.

TERLIVAZ®, recognized as the first and only FDA-approved treatment for improving kidney function in adults suffering from HRS-AKI, offers a beacon of hope. This therapy could potentially alter the treatment landscape significantly for individuals facing this life-threatening condition.

Key Insights from the Presentation

The presentation titled, "Real-world terlipressin treatment patterns and outcomes in hepatorenal syndrome-acute kidney injury (HRS-AKI): Preliminary data from seven US hospitals," will feature several key authors, including Dr. Stevan A. Gonzalez, Dr. Aanchal Kapoor, and Dr. A. Sidney Barritt IV among others. They will discuss the therapy's effectiveness and delineate treatment patterns observed in real clinical settings, which could help shape future guidelines and best practices.

Safety and Efficacy Considerations

Like any medical treatment, TERLIVAZ® comes with its own set of risks. Patients with elevated serum creatinine levels over 5 mg/dL may not benefit from this therapy. Additionally, serious warning signs include the potential for respiratory failure, especially in patients with a history of volume overload or acute-on-chronic liver failure. As Keenova outlines in its safety information, it is paramount to monitor patients closely during treatment.

Keenova also includes formal contraindications for the use of TERLIVAZ® in individuals experiencing hypoxia or those with existing ischemic conditions. Monitoring oxygen levels and physician discretion are critical components in the treatment approach to ensure patient safety and optimal outcomes.

A Step Forward for Patient Care

Keenova's commitment to transforming care for patients impacted by rare and intricate medical conditions is underscored by its development of TERLIVAZ®. The organization strives to enhance therapeutic solutions across various healthcare domains, including nephrology and pulmonary care. As this new data emerges from the Digestive Disease Week presentation, it marks another pivotal moment in advancing understanding and refining medical practices concerning HRS-AKI treatment.

In conclusion, as Keenova positions itself at the forefront of therapeutics innovation, the data to be presented at DDW could provide crucial insights not only for clinicians and researchers but for all stakeholders engaged in addressing the challenges posed by hepatorenal syndrome. The information could have significant implications for patient outcomes, informing both existing treatment paradigms and future research avenues aimed at combating this critical health issue.